HeartBeam (NASDAQ: BEAT) has been initiated with a Buy rating and $4 price target by Roth Capital Partners, which highlighted the company’s near-term catalyst of expected FDA clearance for its groundbreaking 12-lead ECG synthesis software. The report cites BEAT’s compact, credit card-sized, cable-free device capable of synthesizing a full 12-lead ECG as a breakthrough in remote cardiac monitoring. Roth’s analysts, led by Kyle Bauser, Ph.D., view BEAT as undervalued given its strong clinical validation, lean cost structure, and potential to redefine how arrhythmias are detected and treated in decentralized care environments.
Roth’s initiation notes that HeartBeam’s pivotal VALID-ECG study (n=198) demonstrated a 93.4% diagnostic agreement between its synthesized ECG and standard 12-lead systems, supporting reliability in arrhythmia assessment. FDA clearance for the synthesis software is anticipated by the end of 2025, enabling a targeted commercial rollout in concierge and preventive cardiology markets before wider adoption. The firm’s model projects profitability by 2027 and estimates revenue of $20 million by 2028, supported by 70% gross margins and scalable recurring revenue streams.
Roth Capital applied a 9x EV/sales multiple to its FY28 estimate, discounted two years at 10%, to arrive at the $4 target. The firm compared HeartBeam’s valuation potential to precedent transactions such as Preventice Solutions’ $1.2 billion acquisition (8x LTM sales) and BioTelemetry’s $2.8 billion buyout (6x LTM sales). Roth concludes that BEAT’s AI-driven diagnostic precision, regulatory readiness, and first-mover advantage in 12-lead remote monitoring position it as a compelling opportunity within the high-growth medical technology and digital health sectors.
To view the full report, visit https://ibn.fm/FcW8B
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is under FDA review. The Company holds over 20 issued patents related to technology enablement.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
About AINewsWire
AINewsWire (“AINW”) is a specialized communications platform with a focus on the latest advancements in artificial intelligence (“AI”), including the technologies, trends and trailblazers driving innovation forward. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, AINW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, AINW brings its clients unparalleled recognition and brand awareness.
AINW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from AINewsWire, text “AI” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit www.AINewsWire.com
Please see full terms of use and disclaimers on the AINewsWire website applicable to all content provided by AINW, wherever published or re-published: https://www.AINewsWire.com/Disclaimer
AINewsWire
Austin, Texas
www.AINewsWire.com
512.354.7000 Office
Editor@AINewsWire.com
AINewsWire is powered by IBN
